|
|
 |
|
Viewing report
|
|
|
|
Merck KGaA: PharmaVitae Report
Datamonitor, Oct 2011, Pages: 70
This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
- Gain insight into Merck KGaA's strategic outlook across the next 6 years.
Highlights
Strategic insight into the prospects for Merck KGaA over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sector.
- Discover how the monoclonal antibody Erbitux (cetuximab) will drive sales growth and help diversify the company’s molecule type strategy out to 2016
- Assess how the withdrawal of Movectro (cladribine) has impacted the company’s core multiple sclerosis franchise
|
|
|
|
